title: Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities.
abstract: Infants with aortic arch interruption of juxtaductal coarctation of the aorta may depend on patency of the ductus arteriosus to provide adequate lower body perfusion. In many such infants the ductus arteriosus constricts after birth, resulting in severe heart failure, poor systemic perfusion and acidemia. We infused prostaglandin E1 (PGE1) at a rate of 0.05--0.1 microgram/kg/min into seven infants with aortic arch interruption and eight infants with coarctation. In one infant in each group the ductus arteriosus was already closed and did not reopen. In one infant with coarctation an adequate trial was not accomplished, and in another adequate pressure measurements were not obtained. Of the remaining 11, the ductus arteriosus was effectively dilated by PGE1 in 10 infants. This was evidenced by an increase in descending aortic blood pressures and a reduction in the pressure difference between the main pulmonary artery and descending aorta in six infants with aortic arch interruption and between ascending and descending aorta in four infants with coarctation. Lower body perfusion improved and left ventricular failure was improved. The infant who did not respond was 5 months old. There were no complications.
mesh_terms: D001013:Aorta, Thoracic / Q000002:abnormalities*; D001017:Aortic Coarctation / Q000503:physiopathology / Q000628:therapy*; D004106:Dilatation; D004341:Drug Evaluation; D004373:Ductus Arteriosus / Q000187:drug effects*; D004374:Ductus Arteriosus, Patent / Q000150:complications* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007261:Infusions, Intra-Arterial; D008297:Male; D011458:Prostaglandins E / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D011458:Prostaglandins E